Literature DB >> 2058871

Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy.

D R Cragg1, H Z Friedman, J D Bonema, I A Jaiyesimi, R G Ramos, G C Timmis, W W O'Neill, T L Schreiber.   

Abstract

OBJECTIVE: To determine what proportion of patients with acute myocardial infarction are not eligible for thrombolytic therapy and to assess their natural history.
DESIGN: Retrospective chart review.
SETTING: A large community-based hospital. PATIENTS: All patients with acute myocardial infarction hospitalized during a 27-month period. MEASUREMENTS: Of 1471 patients with acute myocardial infarction, 230 (16%) received thrombolytic therapy according to the protocol and an additional 97 (7%) received nonprotocol thrombolytic therapy, primary coronary balloon angioplasty, or both because of contraindications. The other 1144 patients (78%) did not receive reperfusion therapy. MAIN
RESULTS: The patients who did not receive thrombolytic therapy were older, more likely to be women, and more likely to have a history of hypertension, previous myocardial infarction, or chronic angina (all comparisons, P less than 0.002). An average of 1.9 reasons for exclusion were identified per patient among the ineligible patients. Mortality was fivefold higher among ineligible patients (19%; Cl, 16% to 21%) than among protocol-treated patients (4%; Cl, 1% to 6%) (P less than 0.001). In-hospital mortality rates for excluded patients were 28% (Cl, 23% to 32%) in elderly patients (age, greater than 76 years; n = 396); 29% (Cl, 23% to 35%) in patients with stroke or bleeding risk (n = 209); 17% (Cl, 14% to 20%) in patients with delayed presentation (greater than 4 hours after the onset of chest pain; [n = 599]); 14% (Cl, 11% to 16%) in patients with an ineligible electrocardiogram (ECG) (n = 673); and 26% (Cl, 21% to 32%) in patients with a miscellaneous reason for exclusion (n = 243). Independent predictors of increased mortality were: age greater than 76 years, stroke or other bleeding risk, ineligible ECG, or the presence of two or more exclusion criteria.
CONCLUSIONS: Thrombolytic therapy is currently used in the United States for only a minority of patients with acute myocardial infarction: those who have low-risk prognostic characteristics.

Entities:  

Mesh:

Year:  1991        PMID: 2058871     DOI: 10.7326/0003-4819-115-3-173

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  16 in total

Review 1.  The role of coronary angioplasty and stenting in acute myocardial infarction.

Authors:  A Brodison; R S More; A Chauhan
Journal:  Postgrad Med J       Date:  1999-10       Impact factor: 2.401

Review 2.  Treating myocardial infarction in the post-GUSTO era. A European perspective.

Authors:  M J de Boer; F Zijlstra
Journal:  Pharmacoeconomics       Date:  1997-10       Impact factor: 4.981

Review 3.  Should older patients with acute myocardial infarction receive thrombolytic therapy?

Authors:  B D Williamson; D W Muller; E J Topol
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

4.  Primary PTCA: Possibly the Best, Often the Only Choice for Reperfusion in Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

5.  Primary PTCA in the UK: if not for all, then for whom?

Authors:  N Brooks
Journal:  Heart       Date:  1997-10       Impact factor: 5.994

6.  Myocardial perfusion scintigraphy for assessment of acute ischemic syndromes: can we seize the moment?

Authors:  S A Stowers
Journal:  J Nucl Cardiol       Date:  1995 May-Jun       Impact factor: 5.952

7.  The effect of reduction of door-to-needle times on the administration of thrombolytic therapy for acute myocardial infarction.

Authors:  A D Kelion; A P Banning; M Shahi; J A Bell
Journal:  Postgrad Med J       Date:  1998-09       Impact factor: 2.401

Review 8.  Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients?

Authors:  J Brügemann; P A de Graeff; J van der Meer; K I Lie
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

9.  Experience of primary angioplasty in the United Kingdom.

Authors:  D R Ramsdale; E D Grech
Journal:  Br Heart J       Date:  1995-05

10.  Emergency primary coronary angioplasty in patients with acute myocardial infarction who are unsuitable for intravenous thrombolysis.

Authors:  C J McKenna; M Codd; H A McCann; D D Sugrue
Journal:  Ir J Med Sci       Date:  1995 Oct-Dec       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.